12 Best Performing Healthcare Stocks to Buy Right Now

Page 3 of 10

8. uniQure N.V. (NASDAQ:QURE)

Number of Hedge Fund Holders: 36 

uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developing transformative treatments for severe medical conditions. Its pipeline includes HEMGENIX for hemophilia B and AMT-130, a gene therapy candidate for Huntington’s disease, which has recently attracted significant attention.

In late September 2025, uniQure N.V. (NASDAQ:QURE) announced positive topline results from pivotal Phase I/II trials of AMT-130, showing a 75% slowing of disease progression over three years. These results mark a major milestone and set the stage for a Biologics License Application (BLA) submission to the FDA in early 2026, aiming for near-term market approval.

To support development and commercialization, the business raised $300 million through a public offering and secured a $175 million senior secured term loan. Alongside AMT-130, QURE continues to advance other gene therapy candidates, including AMT-260 for mesial temporal lobe epilepsy, AMT-162 for ALS, and AMT-191 for Fabry disease, highlighting a diversified pipeline targeting rare diseases.

Analysts have responded positively to the firm’s clinical breakthroughs and financial backing, with strong buy ratings and optimistic price targets. The combination of groundbreaking AMT-130 data, robust funding, and a broad pipeline positions uniQure N.V. (NASDAQ:QURE) among the best performing stocks in the healthcare sector, offering potential transformative impact for patients and promising near-term growth for investors.

Page 3 of 10